Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark H Wilcox

Showing results (41-50 of 267) with videos related to

Pageof 27
Sort By:
Infection and Drug Resistance|September 24, 2015
Antibiotic therapy and Clostridium difficile infection - primum non nocere - first do no harmGrace S Crowther, Mark H Wilcox
Current Opinion in Gastroenterology|November 6, 2018
Comparison of the 2010 and 2017 Infectious Diseases Society of America guidelines on the diagnosis and treatment of Clostridium difficile infectionMark H Wilcox, Christopher M Rooney
The Journal of Antimicrobial Chemotherapy|August 7, 2012
Fidaxomicin: a new option for the treatment of Clostridium difficile infectionAlan P Johnson, Mark H Wilcox
Journal of Clinical Microbiology|April 10, 2020
Ultrasensitive Clostridioides difficile Toxin Testing for Higher Diagnostic AccuracyJohanna Sandlund, Kerrie Davies, Mark H Wilcox
Current Opinion in Infectious Diseases|August 29, 2013
Clostridium difficile: biological therapiesJessica Martin, Damian Mawer, Mark H Wilcox
Current Opinion in Gastroenterology|October 1, 2019
Measuring outcomes in complicated intra-abdominal infectionsShadia Ahmed, Mark H Wilcox, Andrew Kirby
Infectious Disease Clinics of North America|August 12, 2025
Making Sense of Differing Guidelines for Clostridioides difficile InfectionKanika Sehgal, Paul Feuerstadt, Mark H Wilcox
The Journal of Antimicrobial Chemotherapy|May 31, 2003
Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gutJane Freeman, Fiona J O'Neill, Mark H Wilcox
Journal of Infection Prevention|May 26, 2018
Impact of <i>Clostridium difficile</i> toxin gene PCR result on decisions to de-isolate patients: Do the ends justify the means?Kirsti A Morris, Kerrie Davies, Mark H Wilcox
Gut Microbes|May 5, 2012
Models for the study of Clostridium difficile infectionEmma L Best, Jane Freeman, Mark H Wilcox
Pageof 27

Showing results (41-50 of 267) with videos related to

Sort By:
Pageof 27
Infection and Drug Resistance|September 24, 2015
Antibiotic therapy and Clostridium difficile infection - primum non nocere - first do no harmGrace S Crowther, Mark H Wilcox
Current Opinion in Gastroenterology|November 6, 2018
Comparison of the 2010 and 2017 Infectious Diseases Society of America guidelines on the diagnosis and treatment of Clostridium difficile infectionMark H Wilcox, Christopher M Rooney
The Journal of Antimicrobial Chemotherapy|August 7, 2012
Fidaxomicin: a new option for the treatment of Clostridium difficile infectionAlan P Johnson, Mark H Wilcox
Journal of Clinical Microbiology|April 10, 2020
Ultrasensitive Clostridioides difficile Toxin Testing for Higher Diagnostic AccuracyJohanna Sandlund, Kerrie Davies, Mark H Wilcox
Current Opinion in Infectious Diseases|August 29, 2013
Clostridium difficile: biological therapiesJessica Martin, Damian Mawer, Mark H Wilcox
Current Opinion in Gastroenterology|October 1, 2019
Measuring outcomes in complicated intra-abdominal infectionsShadia Ahmed, Mark H Wilcox, Andrew Kirby
Infectious Disease Clinics of North America|August 12, 2025
Making Sense of Differing Guidelines for Clostridioides difficile InfectionKanika Sehgal, Paul Feuerstadt, Mark H Wilcox
The Journal of Antimicrobial Chemotherapy|May 31, 2003
Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gutJane Freeman, Fiona J O'Neill, Mark H Wilcox
Journal of Infection Prevention|May 26, 2018
Impact of <i>Clostridium difficile</i> toxin gene PCR result on decisions to de-isolate patients: Do the ends justify the means?Kirsti A Morris, Kerrie Davies, Mark H Wilcox
Gut Microbes|May 5, 2012
Models for the study of Clostridium difficile infectionEmma L Best, Jane Freeman, Mark H Wilcox
Pageof 27